3D Prosthetic Hand For Ukraine

Since the start of the war in Ukraine, the need for prosthetic hands has increased sharply. In Netherlands TU Delft researcher Gerwin Smit has designed a prosthetic hand that can be made through a combination of 3-D printing and laser-cutting, which means that they be produced easily and relatively cheaply in countries that have little money to spend on such things.

These prosthetic hands are already being used in India and now, the Indian technology company Vispala has donated 350 of Smit’s 3D-printed prosthetic hands to war victims in Ukraine, sponsored by the American IT-company, Cisco. Biomechanical engineer Gerwin Smit is the designer of the so-called ‘Hundred Dollar Hand’ which is easy and inexpensive to produce using a combination of 3-D printing and laser-cutting. 80% of people needing a prosthetic hand live in countries which have little money for such things so Smit’s robust and artificial hand offers a robust and reliable solution. Last year, the social enterprise, Vispala made the Hundred Dollar Hand design ready for production and already, several hundred have been made and distributed around India since 2021.
Meanwhile, Gerwin Smit and his team are monitoring the use of these prosthetic hands  and are gathering feedback to see how the design can be made even better.

Source: https://www.tudelft.nl/ 

World’s First COVID-19 DNA Vaccine

 India‘s drug regulator has granted emergency use approval for Zydus Cadila‘s COVID-19 vaccine, the world’s first DNA shot against the coronavirus, in adults and children aged 12 years and above. The approval gives a boost to India’s vaccination programme, which aims to inoculate all eligible adults by December, and will provide the first shot for those under 18, as the country still struggles to contain the virus spread in some states. The vaccine, ZyCoV-D, uses a section of genetic material from the virus that gives instructions as either DNA or RNA to make the specific protein that the immune system recognises and responds to. Unlike most COVID-19 vaccines, which need two doses or even a single dose, ZyCoV-D is administered in three doses.

The generic drugmaker, listed as Cadila Healthcare Ltd, aims to make 100 million to 120 million doses of ZyCoV-D annually and has already begun stockpiling the vaccineZydus Cadila‘s vaccine, developed in partnership with the Department of Biotechnology, is the second home-grown shot to get emergency authorization in India after Bharat Biotech‘s Covaxin. The drugmaker said in July its COVID-19 vaccine was effective against the new coronavirus mutants, especially the Delta variant, and that the shot is administered using a needle-free applicator as opposed to traditional syringes. The regulatory nod makes ZyCoV-D the sixth vaccine authorized for use in the country where only about 9.18% of the entire population has been fully vaccinated so far, according to Johns Hopkins data.

The firm had applied for the authorization of ZyCoV-D on July 1, based on an efficacy rate of 66.6% in a late-stage trial of over 28,000 volunteers nationwide.

https://www.reuters.com/